Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Assets (2018 - 2026)

Exagen filings provide 9 years of Assets readings, the most recent being $52.0 million for Q1 2026.

  • On a quarterly basis, Assets rose 28.94% to $52.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $52.0 million, a 28.94% increase, with the full-year FY2025 number at $58.0 million, up 29.84% from a year prior.
  • Assets hit $52.0 million in Q1 2026 for Exagen, down from $58.0 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $122.0 million in Q1 2022 to a low of $40.3 million in Q1 2025.
  • Median Assets over the past 5 years was $58.8 million (2025), compared with a mean of $67.0 million.
  • Biggest five-year swings in Assets: crashed 40.03% in 2023 and later soared 44.07% in 2025.
  • Exagen's Assets stood at $86.2 million in 2022, then tumbled by 33.96% to $56.9 million in 2023, then fell by 21.52% to $44.7 million in 2024, then grew by 29.84% to $58.0 million in 2025, then fell by 10.45% to $52.0 million in 2026.
  • The last three reported values for Assets were $52.0 million (Q1 2026), $58.0 million (Q4 2025), and $62.8 million (Q3 2025) per Business Quant data.